Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Short-term Investments (2016 - 2025)

Neurocrine Biosciences' Short-term Investments history spans 16 years, with the latest figure at $767.4 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 8.98% year-over-year to $767.4 million; the TTM value through Dec 2025 reached $767.4 million, down 8.98%, while the annual FY2025 figure was $767.4 million, 8.98% down from the prior year.
  • Short-term Investments reached $767.4 million in Q4 2025 per NBIX's latest filing, down from $774.6 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $899.2 million in Q2 2024 to a low of $370.5 million in Q4 2021.
  • Average Short-term Investments over 5 years is $684.2 million, with a median of $758.4 million recorded in 2025.
  • Peak YoY movement for Short-term Investments: plummeted 39.65% in 2021, then soared 100.35% in 2023.
  • A 5-year view of Short-term Investments shows it stood at $370.5 million in 2021, then surged by 96.06% to $726.4 million in 2022, then grew by 7.45% to $780.5 million in 2023, then rose by 8.02% to $843.1 million in 2024, then fell by 8.98% to $767.4 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Short-term Investments are $767.4 million (Q4 2025), $774.6 million (Q3 2025), and $711.6 million (Q2 2025).